mustgrow BIOLOGICS CORP.

Natural Biologic Refined from Mustard Seed

Corporate Presentation

February 2019

Disclaimer

The views expressed herein contain information derived from publically available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. This Presentation should not be relied upon as a recommendation or forecast by MustGrow Biologics Corp. and it's wholly owned subsidiary MPT Mustard Products & Technologies Inc. ("MustGrow").

Certain statements contained herein constitute forward-looking statements. The words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions are intended to identify forward-looking statements. Such statements reflect MustGrow's current views with respect to future events and are subject to certain risks, uncertainties and assumptions (known and unknown). Many factors could cause MustGrow's actual results, performance or achievements to vary from those described herein. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, sought, proposed, believed, estimated or expected. MustGrow does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law.

Note that purchasing securities of MustGrow should be considered a risky investment as the securities are speculative in nature and are appropriate only for investors who are prepared to have their money invested for a long period of time and have the capacity to absorb a loss of some or all of their investment. There is no public market for the securities of MustGrow, and one may never develop, therefore investors may find it difficult to resell their securities.

The securities referred to in this Presentation have not been and will not be registered under the U.S. Securities Act of 1933 or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933 and any other applicable securities laws. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, the securities, nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Table of Contents

MustGrow Biologics – Investment Highlights

- **Agricultural Pesticides & Fertilizers**: The natural biologics market (**US$3.2Bn**)[1] is poised to continue to grow relative to the synthetic pesticide & fertilizer market (**US$250Bn**)[1]
- MustGrow is a private agriculture biotech company focused on commercializing a portfolio of organic & natural bio-pesticides and bio-fertilizers
- MustGrow's **patented** products are derived from mustard seed, utilizing the plant's natural defense mechanism as a **pre-plant/pot soil bio-fumigant/treatment**
  - **$9mm** has been spent on **110** independent tests – remarkably safe & effective
  - MustGrow's *fruit & vegetables* products are registered with **Health Canada** and the **U.S. Environmental Protection Agency (EPA)**
- **Cannabis Application**:
  - Mandatory cannabis testing for pesticides effective January 2019[2]
  - Cannabis cultivators need help controlling pests and diseases
  - MustGrow: Proven control of soil-borne pests & diseases that contaminate facilities
  - Based off of current registrations, new liquid formulation may be fast-tracked for use in Canadian cannabis cultivation
  - Building a ***suite*** of natural biological fumigants, pesticides and fertilizers

[1] *Estimates of Ag biologicals industry based on combination of research data from DunhamTrimmer, Agrow, MarketandMarkets, Frost & Sullivan, Boston Consulting Group, BCC Research, Philips McDougall, Global Industry Analysts, and MarketLine.*

[2] *Health Canada website.*

Agricultural Products: Global Market; Global Problem

Demand for Sustainable Options is Increasing

- Global crop losses are devastating without safe & effective agricultural products
  - Average global yield loss from *Nematodes* (a parasitic worm) is 20% in fruits & vegetables[1]
- There exists a significant opportunity for expansion of natural biologic agricultural products
- ***Biologicals*** can be complementary to, or replace, traditional (and sometimes dangerous) chemistry-based pesticides and fertilizer options
- Rather than using synthetic chemicals, natural biological products may be used by farmers to improve plant health and crop yields



mustgrow BIOLOGICS CORP.

MustGrow sees a significant opportunity in developing biologic products to service the global cannabis and fruits & vegetables markets

MustGrow is developing a suite of natural biologic agricultural products

[1] *Estimates of Ag biologicals industry based on combination of research data from DunhamTrimmer, Agrow, MarketandMarkets, Frost & Sullivan, Boston Consulting Group, BCC Research, Philips McDougall, Global Industry Analysts, and MarketLine.*

MustGrow Products are *Biologics*, Not *Chemistries*

MustGrow's signature mustard-derived products have the efficacious benefits of chemistries and are organic certified



U.S. appeals court orders EPA to ban pesticide said to harm children

Judge Jed Rakoff directed the EPA to ban chlorpyrifos within 60 days, saying the agency failed to counteract scientific evidence that its residue on food causes neurodevelopmental damage to children.

-- Reuters; August 9, 2018

Scientists urge ban of insecticides tied to brain impairment in kids

Even at low levels currently allowed for agricultural use, organophosphates have been linked to lasting brain impairment in children.

-- Reuters; December 6, 2018

France bans crop pesticide metam sodium after people fall ill

The US Environmental Protection Agency (EPA) considers metam sodium a probable human carcinogen … Still, metam sodium is among the most widely used agricultural pesticides in the United States.

-- Reuters; November 5, 2018

Introducing… MustGrow Biologics Corp.

Developing a Portfolio of Biological Products

- **MustGrow** is a **private** agriculture biotech company focused on commercializing a portfolio of organic & natural biologic pesticides, fungicides and stimulants/fertilizers
- MustGrow's signature patented product is derived from mustard seed, utilizing the plant's natural defense mechanism as a **pre-plant soil bio-fumigant**

Why Use Mustard (Brassica) Plants?

Brassica is a genus of plants in the mustard family

- Organic compounds found within Brassica plants form our active ingredient **Allyl Isothiocyanate (AITC)**, and have untapped potential to benefit agricultural production – both as a bio-pesticide/fungicide AND bio-fertilizer
- In our opinion, mustard-derived organic compounds have yet to be fully explored and commercialized
- MustGrow has **concentrated** the active ingredient in granular and liquid form

Safe and effective products from nature

Organic. Natural. Safe.

MustGrow Biologics – 100% Owned Patented I.P.

Agriculture and
Agri-Food Canada

Origin of the Technology

- Originally developed by ***Agriculture and Agri-Food Canada (AAFC)*** in mid-1990's
- *MPT Mustard Products & Technologies Inc. (MPT)* purchased the technology from AAFC and subsequently spent **$9mm on 110 independent tests**, discovering its remarkably efficacious properties as a bio-fumigant and bio-fertilizer
- MustGrow acquired MPT in 2017, now owning 100% of the patented technology

1st Generation: *Granular for fruits & vegetables*

- Granular product mixed with pre-plant/pot soil
- Proven nematicide and fungicide
  - 100% control of RK Nematodes compared to the banded synthetic chemical methyl bromide
- Granular MustGrow **Bio-fertilizer**:
  - Registered with Health Canada (CFRA)
  - Registered with the U.S. Environmental Protection Agency (EPA)
  - Organic Materials Review Institute (OMRI) certified
- Granular MustGrow **Bio-pesticide**:
  - Registered with Health Canada (PMRA)
  - Registered with the EPA in key states excl. California

Health
Canada

MustGrow – 2nd Generation Liquid

2nd Generation: *Liquid Concentration*

- Concentrated liquid delivery platform, utilizing the same active ingredient (*mustard-derived AITC*) as our 1st Generation Granular product
- Increased concentration of AITC in a liquid format; a preference for fruit & vegetable growers
- MustGrow's intellectual property & patent portfolio covers both 1st Generation Granular and 2nd Generation Liquid, plus *composition of matter* and *methods of use* involving mustard & its derivatives as bio-fumigants & bio-fertilizers

Increased Concentration of AITC

4%	27%
1st Gen. Granular	**2nd Gen. Liquid**



MustGrow – Cannabis Industry Focus

Health Canada: Mandatory cannabis testing for pesticides

Effective January 2, 2019

"To meet the testing requirements, licence holders under the Cannabis Regulations must demonstrate that none of the unauthorized pesticide active ingredients, as listed in the Mandatory cannabis testing for pesticide active ingredients - List and limits published by Health Canada, are used to treat their products or have contaminated their products."[1]

Cannabis cultivators need help controlling pests and diseases

- We have already determined that MustGrow's pre-plant/pot soil treatment will control many soil-borne diseases and pests that affect cannabis, including the following:

Soil-borne pests & diseases contaminate cultivation facilities

[1] *Health Canada website.*

Cannabis – Effective Pest & Disease Control

MustGrow is Testing Applications for Cannabis

National Research Council (NRC) & Agriculture and Agri-Food Canada (AAFC)

- Currently testing MustGrow's products as a natural pre-plant/pot soil treatment
- We have already determined that our granular product will control many soil-borne diseases and pests that affect cannabis. MustGrow's pre-plant/pot soil treatment may also control:

Two-Spotted Spider Mite

Alternaria Fungus

Aphids

Fungus Gnats



Thrips

Hemp Russet Mite



Botrytis (Gray Mold)

Control vs. Suppression

- Biologics typically are effective with <75% suppression range, requiring frequent re-entry and re-application intervals
- As a biologic, our product testing indicates more than just suppression, but >**95% control** of soil-borne pests and diseases (in some cases 100% of RK Nematodes compared to Methyl Bromide)

MustGrow & NRC – Control at 24 Hours

Canada
NRC·CNRC

Botrytis (Gray Mold, Bud Rot) is serious and common disease faced by many cannabis cultivators; often brought into facilities via contaminated soil.[1]

Botrytis | + MustGrow Powdered | + MustGrow Liquid

Root rot, such as **Fusarium** & **Rhizocotonia**, wipe out entire cannabis rooms and can lay dormant in the soil for years before it becomes active and detrimental.[1]

Fusarium | + MustGrow Granular | + MustGrow Powdered | + MustGrow Liquid



Rhizocotonia | + MustGrow Granular | + MustGrow Powdered | + MustGrow Liquid

[1] *Royal Queen Seeds website.*

Portfolio Approach for Cannabis Cultivation

In Addition to MustGrow's Signature Bio-Fumigants…

MustGrow is Building a Suite of Biological Products

- Science-based approach to assessing potential product labels from 3rd parties
- Natural and/or organic bio-pesticides & bio-fertilizers
- In-license for private labels (white-label)
- Distribution of current 3rd party product brands

Three Main Product Areas:

Soil Bio-Fumigants

mustgrow BIOLOGICS CORP.

MustGrow Signature Formulations

Bio-Stimulants/Fertilizers



In-License or Distribution

Bio-Control

In-License or Distribution

Fast-Tracked Development for Cannabis Application

Existing Fruit & Vegetables Label with PMRA (Health Canada)

- MustGrow has piggy-backed on its existing approved granular label
- With this existing label, MustGrow's new liquid formulation may be fast-tracked for application in cannabis
- Expected 15-month process, rather than the approximate 5 years for a new product



Management, Directors & Advisors

Corey Giasson – President, CEO & Director

- 20+ years of agriculture experience with a MBA and B.Sc. Ag Economics from the University of Saskatchewan.
- Previous Co-founder & CEO of Rallyemont Energy Inc, sold to Husky Energy.
- Previous Vice President, Business Development & Investor Relations at Anglo Potash Ltd., which sold to BHP in 2008.
- Previous Manager, Market Research at PotashCorp.

Colin Bletsky – COO & Director

- Previous Vice President, BioAg at Novozymes where he was responsible for the BioAg business worldwide.
- 20+ years of experience in agriculture, he has been involved in marketing and sales in many managerial positions.
- Colin holds a Bachelor of Science in Agriculture from the University of Saskatchewan.

Brad Munro – Chairman

- 20+ years as a VP, Investments with a national venture capital firm where he sourced, invested, and managed the activity of over 30 companies and invested $150MM.
- Brad is currently a Director of Secure Energy Services.

Tom Flow – Director

- Founder, Executive Director, Co-CEO of The Flowr Corporation.
- Previous Founder, COO of MedReleaf (sold for $3.2B).
- Widely-recognised for cannabis cultivation thought leadership and expertise.

Matt Kowalski – Director

- Director, VRM Labs.
- Past President & CEO and Natural Industries from 2002-2012.
- Previous Global Market Manager: Bio Control, Novozymes BioAg.

Todd Lahti, CFA, CPA CA – CFO

- +30 years of business experience in finance and operating companies in a multitude of business sectors
- Has closed over 50 M&A, financing and licensing transactions totaling over $2.4 billion
- Previously President of MCN BioProducts Inc., an agricultural technology company, sold to Bunge Ltd. in 2012

Paul Schorn – Market & Research Advisor

- Previous Market Specialist at Dow AgroSciences Canada
- Working with MPT since 2008

Mark Hetherington – Liquid Formulations Scientist

- Current Director of Clinical Research at Canopy Growth Corporation
- Expert in research and formulation for the cannabis and nutraceutical industry

Jamieson Bondarenko, CFA, CMT – Capital Markets Advisor

- Current: Advisor to Lexaria Bioscience Corp., BriaCell Therapeutics Corp.
- Previous Equity Capital Markets roles with Eight Capital, Dundee Securities, Wellington West Capital Markets, HSBC Securities

John Cross – Prior Board Member of MPT

- Recipient of the Order of Canada
- Founder and past CEO of Philom Bios Inc.
- Founder and past Executive Director of the POS Pilot Plant Corporation

Spencer Early – Prior Board Member of MPT

- P. Eng from the University of Saskatchewan
- President of Early's Farm & Garden in Saskatoon, a 104 year old family business that offers a diversified array of products including agricultural and turf products

Capital Structure

Basic Shares Outstanding	23,273,042
Options	2,200,000
Warrants	9,695,200
Fully-Diluted Shares Outstanding	35,168,242
Previous Capital Spent (C$MM)	$9.0
Debt (C$MM)	$1.0
Cash (C$MM)	$0.5
Insiders & Advisors Ownership (31%)	7,162,507

Warrants include 537,600 warrants underlying Unit Warrants.

Debt has no maturity; no interest payable; no scheduled principal payments. Due upon change of control of MustGrow and/or certain revenue milestones.

Corey Giasson, *President & CEO*
coreyg@mustgrow.ca
p: 306-717-1128

Colin Bletsky, *COO*
colinb@mustgrow.ca
p: 306-241-6095

Disclaimer

Statutory Rights of Action in the Event of a Misrepresentation for Investors in Alberta

In the event that this prospectus, as determined by Alberta law, has a misrepresentation, Alberta residents have a statutory right of action for damages against: (a) the issuer or a selling security holder on whose behalf the distribution was made; (b) each underwriter of the securities that is in a contractual relationship with the issuer or selling security holder on whose behalf the distribution is made; (c) every director of the issuer at the time the prospectus was filed; (d) every person or company whose consent to disclosure of information in the prospectus has been filed but only with respect to reports, opinions or statements that have been made by them; and (e) every person or company who signed the prospectus. The right to action for damages against the above mentioned persons exist without regard to whether the purchaser relied on the misrepresentation. In the alternative, a purchaser who purchases a security offered by it during the period of distribution has a right of action for rescission against: (a) the issuer or a selling security holder on whose behalf the distribution is made; and (b) every underwriter of the securities. The right of action for rescission against the above mentioned persons exist without regard to whether the purchaser relied upon the misrepresentation.

There are various defences available to the persons or companies that you have a right to sue. In particular, they have a defence if you knew of the misrepresentation when you purchased the shares. If you intend to rely on the rights described in (a) or (b) above, you must do so within strict time limitations. You must commence your action to cancel the agreement within 180 days after the date of the transaction that gave rise to the cause of action. You must commence your action for damages within the earlier of 180 days after you first had knowledge of the facts giving rise to the cause of action, or three (3) years after the date of the transaction that gave rise to the cause of action.

Statutory Rights of Action in the Event of a Misrepresentation for Investors in Saskatchewan

In the event that this prospectus, as determined by Saskatchewan law, has a misrepresentation, Saskatchewan residents have a statutory right to sue: (a) the issuer to cancel your agreement to buy the shares, or (b) for damages against: (i) the issuer; (ii) every underwriter of the securities that is in a contractual relationship with the issuer; (iii) every director of the issuer at the time the prospectus was filed; (iv) every person or company whose consent to disclosure of information in the prospectus has been filed but only with respect to reports, opinions or statements that have been made by them; and v) every person or company that in addition to the persons or companies mentioned in (i)-(iv) signed the prospectus or the amendment to the prospectus. In addition, if there is a misrepresentation in any "advertising or sales literature" distributed in connection with this prospectus and you are a resident of Saskatchewan, you have a statutory right to sue: (a) the issuer; (b) every promoter and director of the issuer at the time the advertising or sales literature was distributed; and (c) every person who, or company that, at the time the advertising or sales literature was distributed, sells shares on behalf of the issuer. Furthermore, if there is a misrepresentation in any verbal statement made to you relating to the shares that was a misrepresentation at the time of purchase, the verbal statement was made either before or contemporaneously with the purchase of the shares and you are resident in Saskatchewan you have a statutory right to sue the individual who made the verbal statement. These statutory rights of action are available to you whether or not you relied on the misrepresentation. However, there are various defences available to the persons or companies that you have a right to sue. In particular, they have a defence if you knew of the misrepresentation when you purchased the shares. If you intend to rely on the rights described above, you must do so within strict time limitations. You must commence your action to cancel the agreement within 180 days after the date of the transaction that gave rise to the cause of action. You must commence your action for damages within the earlier of one (1) year after you first had knowledge of the facts giving rise to the cause of action, or six (6) years after the date of the transaction that gave rise to the cause of action.

Disclaimer

Statutory Rights of Action in the Event of a Misrepresentation for Investors in Manitoba
In the event that this prospectus, as determined by Manitoba law, has a misrepresentation, the purchaser is deemed to have relied on the misrepresentation and Manitoba residents have a statutory right to sue: (a) the issuer to cancel your agreement to purchase the shares; or (b) for damages against: (i) the issuer; (ii) each underwriter of the securities that is in a contractual relationship with the issuer; (iii) every director of the issuer at the time the prospectus was filed; (iv) every person or company whose consent to disclosure of information in the prospectus has been filed, but only with respect to reports, opinions or statements that have been made by them; and (v) every person or company, other than the ones referred to in (i)-(iv), who signed the prospectus. If you choose to cancel your agreement to buy the shares, you will have no right of action for damages against any person referred to above. There are various defences available to the persons or companies that you have a right to sue. In particular, they have a defence if you knew of the misrepresentation when you purchased your shares. If you intend to rely on the rights described in (a) or (b) above you must commence your action to cancel the agreement within 180 days after you singed the agreement to purchase the shares. You must commence your action for damages within the earlier of 180 days after learning of the misrepresentation and two (2) years after you signed the agreement to purchase the shares.

Statutory Rights of Action in the Event of a Misrepresentation for Investors in Ontario
In the event that this prospectus, as determined by Ontario law, has a misrepresentation, Ontario residents have a statutory right to sue: (a) the issuer to cancel your agreement to purchase the shares; or (b) for damages against: (i) the issuer; (ii) each underwriter of the securities who is required to sign the certificate required by section 59 of the Ontario Securities Act; (iii) every director of the issuer at the time the prospectus was filed; (iv) every person or company whose consent to disclosure of information in the prospectus has been filed pursuant to a requirement of the regulations but only with respect to reports, opinions or statements that have been made by them; and (v) every person or company who signed the prospectus other than the persons or companies included in clauses (i)-(iv). Any person who chooses to cancel their agreement to purchase shares will have no action to sue for damages. This statutory right to sue is available to you whether or not you relied on the misrepresentation. There are various defences available to the persons or companies that you have a right to sue. In particular, they have a defence if you knew of the misrepresentation when you purchased your shares. However, there are strict time limitations. You must commence your action to cancel the agreement within 180 days after you signed the agreement to purchase the shares. You must commence your action for damages within the earlier of 180 days after learning of the misrepresentation and three (3) years after you signed the agreement to purchase the shares.

Statutory Rights of Action in the Event of a Misrepresentation for Investors in Nova Scotia
In the event that this prospectus, as determined by the law in Nova Scotia, has a misrepresentation, residents of Nova Scotia have a statutory right to sue: (a) the issuer to cancel your agreement to purchase the shares; or (b) for damages against: (i) the issuer; (ii) each underwriter of the securities that is in a contractual relationship with the issuer; (iii) every director of the issuer at the time the prospectus was filed; (iv) every person or company whose consent to disclosure of information in the prospectus has been filed pursuant to a requirement of the regulations but only with respect to reports, opinions or statements that have been made by them; and (v) every person or company who signed the prospectus other than the persons or companies included in clauses (i)-(iv). If you choose to cancel your share purchase you will no longer have a right of action to sue any of the persons named above for damages.
This statutory right is available to you whether or not you relied on the misrepresentation. However, there are various defences available to the persons that you have a right to sue. In particular, they have a defence if you knew of the misrepresentation when you purchased your shares. If you intend to rely on the rights described in (a) or (b) above, you must do so within strict time limitations. You must commence your action to cancel the agreement within 180 days after you signed the agreement to purchase the shares. You must commence your action for damages within the earlier of 180 days after learning of the misrepresentation and three (3) years after you signed the agreement to purchase the shares. Notwithstanding these time periods, no action shall be commenced to enforce any such rights of rescission or damages more than 120 days after the date on which payment was made for the shares.